X

Trial Profile

A Phase II Trial to Assess the Activity of NY-ES-O1 Targeted T Cells in Advanced Oesophagogastric Cancer

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 07 Nov 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Letetresgene autoleucel (Primary) ; Cyclophosphamide; Fludarabine; Interleukin-2
Indications Gastric cancer; Oesophageal cancer
Focus Therapeutic Use
Acronyms ATTACK-OG; Y-ESO1OG

Most Recent Events

30 Jun 2019 Trial has been discontinued in UK, according to European Clinical Trials Database record.
07 Aug 2018 According to the ClinicalTrials.gov record, the study was terminated in United Kingdom due to Withdrawal of funding.
02 May 2018 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com